Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 6, 2012, Pages 1055-1061

  Miller, C H ^a   Platt, S J ^a   Rice, A S ^a   Kelly, F ^a   Soucie, J M ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Factor IX; Factor VIII; Inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; CENTRIFUGATION; CONTROLLED STUDY; CRYOPRESERVATION; HEAT TREATMENT; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MAJOR CLINICAL STUDY; NIJMEGEN BETHESDA ASSAY MODIFICATION; PRIORITY JOURNAL; TIME;

ANTIBODIES; ANTIGEN-ANTIBODY REACTIONS; ARTIFACTS; BLOOD COAGULATION TESTS; CALIBRATION; COAGULANTS; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HOT TEMPERATURE; HUMANS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN DENATURATION; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84861673289     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04705.x     Document Type: Article

References (14)

1. Kasper CK, Aledort LM, Counts RB, Edson JR, Frantantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Schulman NR, van Eys J. A more uniform measurement of factor VIII inhibitors. Thrombos Diathes Haemorrh 1975; 34: 869-72.
2. Peerschke EIB, Castellone DD, Ledford-Kraemer M, van Cott EM, Meijer P, NASCOLA Proficiency Testing Committee. Laboratory assessment of factor VIII inhibitor titer. Am J Clin Pathol 2009; 131: 552-8.
3. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
4. Verbruggen B, van Heerde W, Novakova I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 2002; 88: 362-4.
5. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I, Association of Hemophilia Centre Directors of Canada. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in the haemophilia A population of Canada. Thromb Haemost 1998; 79: 872-5.
6. Reber G, Aurousseau MH, Dreyfus M, Delahousse B, Caron C, Trzeciack MC, Aillaud MF, Horellou MH, Laurian Y, Sie P. Inter-laboratory variability of the measurement of low titer factor VIII:C inhibitor in haemophiliacs: improvement by the Nijmegen modification of the Bethesda assay and the use of common lyophilized plasmas. Haemophilia 1999; 5: 292-3.
7. Kitchen S, Jennings I, Preston FE, Kitchen DP, Woods TAL, Walker ID. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK National Quality External Assessment Scheme for Blood Coagulation. Semin Thromb Hemost 2009; 35: 778-85.
8. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the External Quality Assessment Program of the ECAT Foundation. Semin Thromb Hemost 2009; 35: 786-93.
9. Favaloro EJ, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost 2009; 35: 794-805.
10. Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Hooper WC, the Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in U.S. hemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia 2011; DOI:.
11. Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Semin Thromb Hemost 2009; 35: 760-8.
12. Verbruggen B, van Heerde WL, Laros-Gorkom BAP. Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen. Semin Thromb Hemost 2009; 35: 752-9.
13. Gilles JGG, Amout J, Vermylen J, Saint-Remy JMR. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
14. Aligman M, Dietrich G, Nydegger UE, Boieldieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (antihemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 1992; 89: 3795-9.